Clinical Trials Logo

Clinical Trial Summary

This study will evaluate the efficacy, safety, pharmacokinetics(PK) ,pharmacodynamics and anti-drug antibodies(ADA) of MIL62 compared with cyclosporine in participants with primary membranous nephropathy (pMN).


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT05862233
Study type Interventional
Source Beijing Mabworks Biotech Co., Ltd.
Contact Minghui Zhao, Doctor
Phone 8610-83572388
Email mhzhao@bjmu.edu.cn
Status Recruiting
Phase Phase 3
Start date June 2, 2023
Completion date June 2026

See also
  Status Clinical Trial Phase
Recruiting NCT05800873 - Evaluate The Efficacy, Safety, Pharmacokinetics And Pharmacodynamics Of EVER001 Phase 1
Recruiting NCT05514015 - Clinical Study of Rituximab Combined With Corticosteroids or Rituximab Monotherapy in the Treatment of Primary Membranous Nephropathy Phase 4
Recruiting NCT05668403 - A Phase I Clinical Study of Recombinant Humanized Anti-CD20(B-lymphocyte Antigen CD20) Monoclonal Antibody Subcutaneous Injection in the Treatment of Primary Membranous Nephropathy Phase 1
Recruiting NCT05696613 - A Study of SNP-ACTH (1-39) Gel in Patients With Primary Membranous Nephropathy Phase 3
Active, not recruiting NCT04629248 - A Study Evaluating the Efficacy and Safety of Obinutuzumab in Participants With Primary Membranous Nephropathy Phase 3
Not yet recruiting NCT06466135 - Study of WAL0921 in Patients With Glomerular Kidney Diseases Phase 2
Not yet recruiting NCT06120673 - REmission in Membranous Nephropathy International Trial (REMIT) Phase 3
Recruiting NCT05398653 - A Clinical Study of MIL62 in Primary Membranous Nephropathy Phase 1/Phase 2
Active, not recruiting NCT05136456 - Evaluate the Efficacy and Safety of SHR1459 Tablets in Patients With Primary Membranous Nephropathy Phase 2
Recruiting NCT05707377 - A Study to Evaluate the Safety and Efficacy of Zanubrutinib in Participants With Primary Membranous Nephropathy Phase 2/Phase 3